Literature DB >> 799548

Pharmacokinetics in patients with cardiac failure.

N L Benowitz, W Meister.   

Abstract

Cardiac failure is often associated with disturbances in cardiac output, autonomic nervous system activity, central and systemic venous pressures, and sodium and water metabolism. These disturbances influence the extent and pattern of tissue perfusion, may lead to tissue hypoxia and visceral congestion, and may alter gastrointestinal motility. By these mechanisms, cardiac failure potentially affects absorption and disposition characteristics of drugs, which may necessitate adjustment in dosage regimen for optimum therapy. Lignocaine is the drug which has been studied most extensively in cardiac failure. Volumes of distribution and clearance are decreased. As a drug whose metabolism is largely limited by liver blood flow, decreased blood flow to the liver accounts for some of the change in clearance, but impaired hepatic metabolism appears also to play a role in some patients. Accumulation of active metabolites of lignocaine and procainamide in patients with cardiac failure can influence therapeutic and toxic effects. Theophylline metabolism, which is largely independent of blood flow, appears to be reduced significantly in patients with severe cardiac failure and necessitates reduction of dosage. In the presence of severe cardiac failure, digoxin clearance may be less than anticipated on the basis of estimates of renal function. Quinidine plasma levels may be higher after single doses due to reduced volume of distribution. Quinidine metabolites are believed not to be pharmacologically active but may create confusion with nonspecific assays. Specific assays are recommended in cardiac failure, especially complicated by renal insufficiency. Data are lacking relating pharmacokinetic alterations to haemodynamic measurements in patients with cardiac failure. Whereas the direction of change in pharmacokinetic parameters may be predicted, variability in the magnitude of change is so great that determination of drug concentration in blood remains as essential adjunct to therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 799548     DOI: 10.2165/00003088-197601060-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  72 in total

1.  Malabsorption as a complication of congestive heart failure.

Authors:  D BERKOWITZ; M N CROLL; W LIKOFF
Journal:  Am J Cardiol       Date:  1963-01       Impact factor: 2.778

2.  Intramuscular injection of drugs.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

3.  Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance.

Authors:  M W Weinberger; R A Matthay; E J Ginchansky; C A Chidsey; T L Petty
Journal:  JAMA       Date:  1976-05-10       Impact factor: 56.272

4.  Mucosal blood circulation and its influence on passive absorption in the small intestine. An experimental study in the cat.

Authors:  J Svanvik
Journal:  Acta Physiol Scand Suppl       Date:  1973

Review 5.  Clinical applications of the pharmacokinetics of lidocaine.

Authors:  N L Benowitz
Journal:  Cardiovasc Clin       Date:  1974

6.  Quinidine elimination in patients with congestive heart failure or poor renal function.

Authors:  K M Kessler; D T Lowenthal; H Warner; T Gibson; W Briggs; M M Reidenberg
Journal:  N Engl J Med       Date:  1974-03-28       Impact factor: 91.245

7.  Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency.

Authors:  S Bellet; L R Roman; A Boza
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

Review 8.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.

Authors:  L F Prescott; K K Adjepon-Yamoah; R G Talbot
Journal:  Br Med J       Date:  1976-04-17

Review 10.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

View more
  45 in total

1.  Serum alpha-1-acid glycoprotein and protein binding of disopyramide in patients with congestive heart failure.

Authors:  A Nomura; H Yasuda; T Kobayashi; S Kishino; N Kohri; K Iseki; K Miyazaki
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure.

Authors:  A Meissner; S Petersenn; H T Heidemann; U Osterkamp; R Simon; H M Schulte
Journal:  Klin Wochenschr       Date:  1991-03-18

3.  Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".

Authors:  Guo-Fu Li; Xiao Gu; Guo Yu; Shui-Yu Zhao; Qing-Shan Zheng
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 4.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 5.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

Review 6.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

7.  Metabolism of procainamide in patients with chronic heart failure, chronic respiratory failure and chronic renal failure.

Authors:  P du Souich; S Erill
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

Review 8.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.

Authors:  E J Begg; R A Robson; H Ikram; A M Richards; J A Bammert-Adams; S C Olson; E L Posvar; P A Reece; A J Sedman
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

10.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.